CIR exerts antitumor effect by triggering immune response, characterized by increased CD4+ T cells and macrophages in tumor, enhanced CD8+ T cells and T effector memory cells in spleen, improved IFN‐γ production of CD8+ tumor‐infiltrating lymphocytes, and reduced exhausted T cells in tumor and spleen. Here, CD8A is linked to neoplasm.